Mineralocorticoid receptor antagonists reduce inflammatory signaling independent of myofiber mineralocorticoid receptor [PDF]
Endocrine and Metabolic ScienceChronic inflammation is a feature of Duchenne muscular dystrophy (DMD), a degenerative striated muscle disease. Mineralocorticoid receptor (MR) antagonists (MRAs) have demonstrated clinical benefit on later onset DMD cardiomyopathy, and preclinical ...
Jeovanna Lowe +5 more
doaj +2 more sources
Cardiovascular-Kidney-Metabolic Effects: Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists [PDF]
Reviews in Cardiovascular MedicineCardiovascular (CV)-kidney-metabolic (CKM) syndrome is a complex disorder characterized by the co-occurrence of CV risk factors, including chronic kidney disease (CKD), hypertension, and metabolic dysfunction, which creates a vicious cycle where one ...
Biykem Bozkurt +2 more
doaj +2 more sources
Mineralocorticoid receptor antagonists in heart failure: a systematic review and meta-analysis [PDF]
Frontiers in Cardiovascular MedicineBackgroundMineralocorticoid receptor over-activation drives maladaptive myocardial fibrosis, vascular inflammation and renal sodium retention across the entire spectrum of left ventricular ejection fraction (LVEF).
Yue Zhang +10 more
doaj +2 more sources
Endogenous bufadienolides, mineralocorticoid receptor antagonists and fibrosis in chronic kidney disease [PDF]
Frontiers in PharmacologyEvery year millions die prematurely of complications related to chronic kidney disease (CKD). Main causes of death are connected with cardiovascular (CV) complications.
Mai Rosenberg, Alexei Y. Bagrov
doaj +2 more sources
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
Pharmaceuticals, 2021 Diabetes mellitus is a global health issue and main cause of chronic kidney disease. Both diseases are also linked through high cardiovascular morbidity and mortality. Diabetic kidney disease (DKD) is present in up to 40% of diabetic patients; therefore,
Nina Vodošek Hojs +5 more
doaj +3 more sources
Thiazides and mineralocorticoid receptor antagonists in chronic kidney disease [PDF]
Romanian Journal of Medical Practice, 2022 The latest treatment guidelines for patients with arterial hypertension continues to indicate as the first line therapy a minimal association between renin-angiotensin system (RAS) blockers and a thiazide-type or a thiazide-like diuretic.
Andrei Niculae +5 more
doaj +1 more source
Vascular cell‐specific roles of mineralocorticoid receptors in pulmonary hypertension
Pulmonary Circulation, 2021 Abnormalities that characterize pulmonary arterial hypertension include impairment in the structure and function of pulmonary vascular endothelial and smooth muscle cells.
Divya P. Menon +10 more
doaj +1 more source
Mineralocorticoid Receptor Antagonists Mitigate Mitral Regurgitation-Induced Myocardial Dysfunction
Cells, 2022 Mitral regurgitation (MR), the disruption of the mitral valve, contributes to heart failure (HF). Under conditions of volume overload, excess mineralocorticoids promote cardiac fibrosis.
Wei-Ting Chang +7 more
doaj +1 more source
New Therapies on the Horizon for Preventing the Progression of Chronic Kidney Disease in Childhood
Çocuk Dergisi, 2023 The purpose of the review is to summarize the current pharmacological management of chronic kidney disease (CKD) in pediatric patients and critically present emerging evidence for the use of mineralocorticoid receptor antagonists and sodium-glucose ...
Siobhan Wagner +2 more
doaj +1 more source
PATIENT WITH CHRONIC HEART FAILURE. RATIONAL CHOICE OF THERAPY
Рациональная фармакотерапия в кардиологии, 2017 The theory of chronic hyperactivation of neurohormonal systems, in particular, sympathoadrenal and renin-angiotensin-aldosterone, is the basis of modern concepts of the pathogenesis of heart failure. The medicinal blocking of these two systems has proved
O. M. Drapkina, D. U. Akasheva
doaj +1 more source